Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the "go ahead" from European ...

AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at ASCO 2026: Rahway, New Jersey Wednesday, May 13, 2026, 11:00 Hrs [IST ...